Xinbin Zhou

Dr. Xinbin Zhou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in Angiology
Verified
Journal Article
Closed access
XZXinbin Zhou
Xinbin Zhou
JDJin Dai
Jin Dai
XXXiaoming Xu
Xiaoming Xu
ZWZhijun Wang
Zhijun Wang
HXHaibin Xu
Haibin Xu
WMWei Mao
Wei Mao
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. Statin treatment has been shown to be associated with reduced risk of CI-AKI; however, the results are inconsistent, especially for patients with chronic kidney disease (CKD). Thus, we conducted a network meta-analysis to evaluate the effects of statins in the prevention of CI-AKI. We systematically searched several databases (including, Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov) from inception to January 31, 2018. The primary outcome was occurrence of CI-AKI in patients with CKD undergoing cardiac catheterization. Both pairwise and network meta-analysis were performed. Finally, 21 randomized controlled trials with a total of 6385 patients were included. Results showed that statin loading before contrast administration was associated with a significantly reduced risk of CI-AKI in patients with CKD undergoing cardiac catheterization (odds ratio: 0.46; P < .05). Atorvastatin and rosuvastatin administered at high dose may be the most effective treatments to reduce incidence of CI-AKI, with no difference between these 2 agents.

9 September 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CWChenxia Wu
Chenxia Wu
XLXinyi Li
Xinyi Li
ZLZhengtian Lv
Zhengtian Lv
QCQian Chen
Qian Chen
YLYang Lou
Yang Lou
XZXinbin Zhou
Xinbin Zhou
Catheter ablation has been recommended for patients with symptomatic atrial fibrillation (AF), with pulmonary vein isolation being the cornerstone of the ablation procedure. Newly developed technologies, such as cryoballoon ablation with a second-generation cryoballoon (CB2) and the contact force radiofrequency (CF-RF) ablation, have been introduced in recent years to overcome the shortcomings of the widely used RF ablation approach. However, high-quality results comparing CB2 and CF-RF remain controversial. Thus, we conducted this meta-analysis to assess the efficacy and safety between CB2 and CF-RF using evidence from randomized controlled trials (RCTs). Databases including Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov were systematically searched from their date of inception to January 2021. Only RCTs that met the inclusion criteria were included for analysis. The primary outcome of interest was freedom from atrial tachyarrhythmia (AT) during follow-up. Secondary outcomes included procedure-related complications, procedure time and fluoroscopy time. Six RCTs with a total of 987 patients were finally enrolled. No significant differences were found between CB2 and CF-RF in terms of freedom from AT (relative risk [RR] = 1.03, 95% confidence interval [CI] 0.92–1.14,p = 0.616) or total procedural-related complications (RR = 1.25, 95% CI 0.69–2.27,p = 0.457). CB2 treatment was associated with a significantly higher risk of phrenic nerve palsy (PNP) than CF-RF (RR = 4.93, 95% CI 1.12–21.73,p = 0.035). The occurrences of pericardial effusion/tamponade and vascular complications were comparable between the CB2 and CF-RF treatments (RR = 0.41,p = 0.398; RR = 0.82,p = 0.632). In addition, CB2 treatment had a significantly shorter procedure time than CF-RF (weighted mean difference [WMD] = − 20.75 min, 95% CI − 25.44 ~ − 16.05 min,P < 0.001), whereas no difference was found in terms of fluoroscopy time (WMD = 4.63 min,p = 0.179). CB2 and CF-RF treatment are comparable for AF patients regarding freedom from AT and procedure-related complications. Compared to CF-RF, CB2 treatment was associated with a shorter procedure time but a higher incidence of PNP. Further large-scale studies are warranted to compare these two techniques and provide an up-to-date recommendation.

20 March 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
TZTiantian Zheng
Tiantian Zheng
CMChenchen Meng
Chenchen Meng
ZLZhengtian Lv
Zhengtian Lv
CWChenxia Wu
Chenxia Wu
XZXinbin Zhou
Xinbin Zhou
WMWei Mao
Wei Mao
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.

4 August 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YKYoujin Kong
Youjin Kong
CYChao Yang
Chao Yang
LXLingling Xie
Lingling Xie
YZYan Zhao
Yan Zhao
ZRZheng Rong
Zheng Rong
WMWei Mao
Wei Mao
Radiation-induced heart disease (RIHD) represents a major dose-limiting complication of thoracic radiotherapy, with a multifaceted pathogenesis involving endothelial dysfunction, chronic oxidative stress, and progressive fibrotic remodeling. Emerging evidence reveals distinct molecular mechanisms underlying RIHD’s heterogeneous clinical manifestations, including pericarditis, accelerated coronary artery disease, cardiomyopathy, valvular degeneration, and conduction abnormalities—which often manifest after prolonged latency periods. Modern radiotherapy techniques have reduced but not eliminated cardiac toxicity, particularly in high-risk populations. Advanced imaging modalities and biomarkers now enable earlier detection, though diagnostic challenges persist. While current management remains largely extrapolated from conventional cardiovascular therapies, novel targeted interventions show preclinical promise. This review synthesizes contemporary understanding of RIHD pathophysiology, risk stratification paradigms, and evolving cardioprotective strategies, while highlighting critical knowledge gaps requiring translational investigation to optimize outcomes for cancer survivors.

8 January 2025 in Chemico-Biological Interactions
Verified
Journal Article
Open access
CMChenchen Meng
Chenchen Meng
YWYali Wang
Yali Wang
TZTiantian Zheng
Tiantian Zheng
ZRZheng Rong
Zheng Rong
ZLZhengtian Lv
Zhengtian Lv
WMWei Mao
Wei Mao
As a fundamental component of antitumor therapy, chemotherapy-induced cardiotoxicity (CIC) has emerged as a leading cause of long-term mortality in patients with malignant tumors. Unfortunately, there are currently no effective therapeutic preventive or treatment strategies, and the underlying pathophysiological mechanisms of CIC remain inadequately understood. A growing number of studies have shown that different mechanisms of cell death, such as apoptosis, pyroptosis, and necroptosis, are essential for facilitating the cardiotoxic effects of chemotherapy. The PANoptosis mode represents a highly synchronized and dynamically balanced programmed cell death (PCD) process that integrates the principal molecular characteristics of necroptosis, apoptosis, and pyroptosis. Recent research has revealed a significant correlation between PANoptosis and the apoptosis of tumor cells. Chemotherapy drugs can activate PANoptosis, which is involved in the development of cardiovascular diseases. These findings suggest that PANoptosis marks the point where the effectiveness of chemotherapy against tumors overlaps with the onset and development of cardiovascular diseases. Furthermore, previous studies have demonstrated that CIC can simultaneously induce pyrodeath, apoptosis, and necrotic apoptosis. Therefore, PANoptosis may represent a potential mechanism and target for the prevention of CIC. This study explored the interactions among the three main mechanisms of PCD, pyroptosis, apoptosis, and necroptosis in CICs and analyzed the relevant literature on PANoptosis and CICs. The purpose of this work is to serve as a reference for future investigations on the role of PANoptosis in the development and mitigation of cardiotoxicity associated with chemotherapy.

5 August 2025 in Phytomedicine
Verified
Journal Article
Open access
CWChenxia Wu
Chenxia Wu
TZTiantian Zheng
Tiantian Zheng
LWLi Wu
Li Wu
ZLZhengtian Lv
Zhengtian Lv
MLMingshuang Li
Mingshuang Li
WMWei Mao
Wei Mao
Traditional Chinese Medicine (TCM), a significant subdiscipline within the realm of complementary medicine, has witnessed a surge in popularity across both Asian and Western nations over the past few decades. It holds potential as an adjunctive therapy for the management of atherosclerotic cardiovascular disease (ACVD). Tanyu Tongzhi Formula (TTF) -a TCM formula with decades of clinical application-has been demonstrated through completed randomized, controlled multicenter clinical studies to extend the maximum exercise duration in patients with chronic coronary syndrome and ameliorate TCM syndromes. TTF emerges as a promising therapeutic candidate for coronary artery disease characterized by phlegm stasis interaction. Additionally, TTF has demonstrated efficacy in protecting against atherosclerosis in murine models. However, the mechanisms by which TTF modulates macrophage function in atherosclerosis remain to be elucidated. To investigate IL-10-dependent efferocytosis regulation as a pivotal mechanism underlying TTF's modulation of macrophage function in atherosclerosis. Low-density lipoprotein receptor or Apolipoprotein E null mice were subjected to a western diet for 8 weeks to induce atherosclerosis, after which they received TTF treatment for an additional 12 weeks. RNA sequencing was employed to identify interleukin-10 (IL-10) as a key downstream molecule. To verify the role of IL-10 in mediating the effects of TTF in reducing atherosclerosis, macrophage-specific IL-10 knockout mice were used. TTF administration significantly alleviated atherosclerosis in mice, evidenced by a reduction in atherosclerotic lesions and plaque necrosis, alongside an augmentation in collagen content. RNA sequencing revealed a substantial upregulation of IL-10 following TTF treatment, which corroborated in various macrophage populations and within mouse atherosclerotic plaques. IL-10 plays a crucial role in mediating the effects of TTF by enhancing macrophage efferocytosis. Notably, the targeted deletion of IL-10 in macrophages attenuated the therapeutic efficacy of TTF in mouse models of atherosclerosis. Furthermore, TTF activated the NF-κB pathway, leading to increased IL-10 expression. Trichosanthes kirilowii and Acorus tatarinowii were identified as the two functional components in TTF. IL-10-mediated efferocytosis potentiation is the critical pathway through which TTF stabilizes atherosclerotic plaques. The NF-κB/IL-10/efferocytosis axis provides a novel pharmacological target for macrophage-directed anti-atherosclerotic therapies. Tanyu Tongzhi Formula participates in the above regulatory mechanism and significantly alleviates atherosclerosis.